REPLAY: Fireside Chat with NanoViricides President & Exec. Chairman Anil R. Diwan

Watch Fireside Chat Below, or Click HERE:

Exec Edge hosted a fireside chat with NanoViricides, Inc. (NYSE: NNVC) President and Executive Chairman Anil R. Diwan, PhD, moderated by IPO Edge Editor-in-Chief John Jannarone and Editor-at-Large Jarrett Banks in a video session lasting approximately 30 minutes.

To watch the replay, CLICK HERE.

Dr. Diwan discussed:

• How NanoViricides’ broad-spectrum antiviral drugs like its lead drug NV-387 work alongside vaccines.
• NanoViricides advancing a broad-spectrum antiviral approach that will be effective even against variants with its lead drug NV-387; how this differ from current antivirals in treating viral diseases like RSV and FLU. 
• The company’s Orphan Drug Designation granted by the FDA and its filing for Rare Pediatric Disease Designation for Measles; how the Company benefits from these designations and the upcoming potential funding benefits.
• The resurgence of Measles despite having a vaccine in place and how it has caused epidemics in Europe, Canada, Mexico, and Bangladesh, while also making headlines in the U.S. Why this is happening and what this return tell us about current protection against viral diseases that are thought to be eliminated by vaccines. 
• The resurgence of several viral infections globally, like Monkeypox and Ebola, and the WHO declaring global alerts as diseases come back with new virus variants for which there is no vaccine or treatment, and how NanoViricides can help. 

Never Miss our Weekly Highlights HERE

About NanoViricides, Inc. (NYSE: NNVC)

NanoViricides, Inc. (the “Company”; NYSE Ticker NNVC) is a clinical stage biopharmaceutical company specializing in the discovery, development, and commercialization of drugs to combat viral infections using its patented and novel nanomedicines technology platform.

The Company’s platform is based on host-mimicry, and thereby has uniquely enabled development of broad-spectrum antiviral drugs that the viruses would be unable to escape, a critical unmet need in antiviral therapeutics. NanoViricides possesses its own debt-free facility that supports research and development and drug discovery, drug candidate optimization, cGMP-compliant drug substance manufacturing, cGMP-compliant manufacturing and packaging of drug products for human clinical trials and early commercialization.

The Company has several drugs in various stages of development including gummies that: don’t need swallowing, can be manufactured in blisterpacks, and can be stored at room temperature for easy use and distribution. NanoViricides, Inc. is domiciled under the laws of the State of Delaware, with its principal operations located in the State of Connecticut. NanoViricides has successfully completed Phase 1 clinical trials of its lead drug NV-387; is initiating Phase 2 of the drug shortly; has been granted Orphan Drug Designation by the US FDA and filed for Rare Pediatric Disease Designation for measles.

READ MORE

Hantavirus Outbreak Shows Need for Broad-Spectrum Antiviral Drugs

About Anil R. Diwan, PhD

Anil Diwan, PhD has been President and Chairman of the Board of NanoViricides, Inc since its founding in 2005. Dr. Diwan spearheaded the Company’s uplisting from the OTC Markets to the NYSE-American stock exchange in 2013, and has led several of the Company’s financing rounds since 2010. He has several patents issued internationally resulting from three fundamental international patent applications.

Dr. Diwan is a brilliant inventor and a serial entrepreneur. For example, he invented novel polymeric micelle-based nanomedicine technologies in 1991, before “nanomedicine” was even understood by others. Prior to co-founding NanoViricides, Inc., he has founded TheraCour Pharma, Inc., a privately held company focused in nanomedicines and cell-targeted drug delivery, and AllExcel, Inc., a company with diverse portfolios including nanomedicines, small chemicals, device technologies, and informatics. He started his career with several NIH SBIR (small business innovation research) grant awards.

Anil started as a Chemical Engineer with a B.Tech. from the Indian Institute of Technology, Mumbai (IIT-B), India and a Ph.D. from Rice University, TX, USA. He then did post-docs in Biomedical Engineering at the University of Wisconsin, and in Virology at the University of Connecticut. Since then, Dr. Diwan has over 25 years of Bio-Pharmaceutical and R&D experience, both as a Researcher and an entrepreneur.

Under Dr. Diwan’s leadership, NanoViricides, Inc. has been able to stay at the leading edge of antiviral therapeutics development across multiple virus families, using the nanoviricide platform technology to develop “first-visit” broad-spectrum antiviral drugs that are effective even as viral variants emerge – all this while keeping both administrative and R&D costs extremely low. Anil Diwan has robustly expanded the company’s broad-spectrum drug pipeline every year, and was recognized as “Researcher of the Year” by BusinessNewHaven, a Connecticut Area Business Journal.

READ MORE

NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA

Contact:

IPO Edge

www.IPO-Edge.com

Editor@IPO-Edge.com

Click HERE to follow us on LinkedIn